Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Relay Therapeutics Inc
(NQ:
RLAY
)
7.060
+0.020 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Relay Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Earnings Outlook For Relay Therapeutics
May 03, 2023
Via
Benzinga
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
April 27, 2023
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present...
Via
Talk Markets
What 11 Analyst Ratings Have To Say About Relay Therapeutics
April 20, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
Relay Therapeutics's Return On Capital Employed Overview
March 01, 2023
Via
Benzinga
Relay Therapeutics Earnings Preview
February 22, 2023
Via
Benzinga
5 Analysts Have This to Say About Relay Therapeutics
September 30, 2022
Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Why Relay Therapeutics Stock Is Trading Higher Today
April 19, 2023
Relay Therapeutics (NASDAQ: RLAY) shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and announced a $29 price target. Also, the stock is rebounding...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
April 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 18, 2023
Via
Benzinga
Expert Ratings for Relay Therapeutics
September 30, 2022
Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings:
Via
Benzinga
4 Analysts Have This to Say About Relay Therapeutics
September 14, 2022
Within the last quarter, Relay Therapeutics (NASDAQ:RLAY) has observed the following analyst ratings:
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 18, 2023
On Tuesday, 91 stocks hit new 52-week lows.
Via
Benzinga
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 18, 2023
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional...
Via
Benzinga
Why Relay Therapeutics Stock Is Plunging Today
April 18, 2023
Relay Therapeutics Inc (NASDAQ: RLAY) announced initial clinical data for RLY-2608, an investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα.
Via
Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
April 18, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
April 13, 2023
Via
Benzinga
Get In Now. 7 Stocks That Are Set to Soar.
April 13, 2023
While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
April 13, 2023
Via
Benzinga
Evogene Offers An Excellent Risk/Reward Ratio
March 21, 2023
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Relay Therapeutics's Earnings Outlook
November 02, 2022
Relay Therapeutics (NASDAQ:RLAY) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Relay...
Via
Benzinga
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022
September 30, 2022
Upgrades
Via
Benzinga
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
September 23, 2022
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.
Via
InvestorPlace
Wells Fargo Slashes Price Target On This Stock By Over 71%, Also Check Out Other Major PT Changes Here
September 14, 2022
Wells Fargo cut the price target on Cabaletta Bio, Inc. (NASDAQ: CABA) from $14 to $4. Wells Fargo analyst Derek Archila maintained the stock with an Overweight rating. Cabaletta Bio shares gained 0.9%...
Via
Benzinga
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
September 14, 2022
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.